Sensory Anesthesia Achieved Through Different Paravertebral Block Approaches for Post-Op Pain Management After VATS Lung Resection
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jul 2, 2025
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to provide pain relief after a type of lung surgery called video-assisted thoracoscopic surgery (VATS), which is a minimally invasive procedure used to treat lung conditions like cancer. The focus is on a pain relief method called the paravertebral block, where numbing medicine is injected near the spine to block pain signals. Researchers want to see which of the two injection methods works better to numb the right areas and reduce pain after surgery, helping to improve comfort during recovery.
Adults aged 18 and older who are having this lung surgery may be eligible to join, as long as they meet certain health criteria and don’t have conditions that make this pain block unsafe (like blood clotting problems or allergies to the numbing medicine). Participants can expect to receive one of the two types of paravertebral blocks during their surgery, and doctors will carefully check how well each method numbs the chest area. This study is not yet recruiting, but if you or a family member are preparing for VATS lung surgery, this trial could offer new insights into better pain management options after the procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 years and older
- • American Society of Anesthesiologists (ASA) score 1-3
- Exclusion Criteria:
- • Contraindication to the paravertebral block (coagulopathy, use of anticoagulants or antiplatelet agents other than aspirin that have not been stopped according to hospital guidelines, thoracoscopic visualization of the paravertebral space expected to be difficult or impossible, anterior spinal surgery with potential discontinuity of the paravertebral space)
- • Epidural analgesia preferred (high risk of thoracotomy, marginal lung function)
- • Surgical criteria: conversion to thoracotomy necessary and thoracic epidural or other form of regional analgesia implemented post-operatively
- • Known allergy to local anesthetics
- • Language barrier, psychiatric, physical or mental condition making pain assessment impossible despite prior education
- • Pregnancy
- • Patient refusal to participate
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Alex Moore, MD
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported